Topic:

M&A

Latest Headlines

Latest Headlines

Adcock Ingram pleads merger essential for survival

Most drugmakers say mergers are what they need to become bigger and more profitable. South Africa's Adcock Ingram say it needs a proposed merger just to survive.

Italy's Menarini looks to significantly build its Indian business

Italian drugmaker Menarini is looking to grow its operations in India. It is bringing some new products to market there but would like to buy some established drug brands if it can find them at the right price.

Thermo snags EU sign-off for $13.6B Life Tech deal

Thermo Fisher is plodding along with its blockbuster agreement to trade $13.6 billion for competitor Life Technologies, picking up European Commission approval on the condition that it sheds a few business units.

Nordic Capital, Wendel in two-way race for $1.6B LTS Lohmann deal

Two buyout firms are duking it out for LTS Lohmann, a drug-patch maker partly owned by Novartis, Reuters reports. Now that the dust has settled on first-round bids, which were due last month, Wendel and Nordic Capital are still in the running for a deal worth about $1.6 billion.

Smith & Nephew's M&A blitz rolls on with Brazilian buy

U.K. orthopedics giant Smith & Nephew has been riding its checkbook into emerging markets all year, and now the company has signed a deal to pick up a share of its Brazilian wound care partner with an eye on vertical integration.

Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth

When Bayer CEO Marijn Dekkers stepped into the job in 2010, he had a trove of cash, and he promised to spend a big chunk on deals. A $23 billion chunk, in fact. Since then, the German conglomerate hasn't exactly been audacious in the M&A arena. Bayer has snapped up a healthcare company or three, but it's quick to back away if a price gets too rich.

UPDATED: Bayer's $2.4B bid to buy Algeta fits neatly with cancer drug strategy

Earlier this year, Bayer happily heralded the FDA's approval of Xofigo for castration-resistant prostate cancer as an important milestone for its steadily growing portfolio of cancer therapies. And now the German pharma company has set its sights on bagging Algeta--the Norwegian company that discovered the therapy and subsequently partnered with Bayer--for $2.4 billion.

Novartis open to JVs, sales, spinoffs, buyouts in strategic review

After Novartis's investor day, the spotlight quickly moved to the company's $5 billion buyback plan. CEO Joe Jimenez and his team also unveiled some details--a few, at least--about the company's strategic review.

Under Icahn's pressure, Hologic's M&A prospects heat up

Now that activist investor Carl Icahn has shown his hand of Hologic shares, the sluggish diagnostic giant is likely to attract some buyout attention, and analysts are split on whether the company should sell itself outright or flip its individual units.

After $2.6B deal, JLL targets more CMOs

Private equity outfit JLL Partners bet big on contract manufacturing last week with its $2.6 billion deal to combine Dutch Royal DSM with its portfolio CMO Patheon, and the fund's co-founder said the company's not done yet.